FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296622375> ?p ?o ?g. }

• W4296622375 endingPage "100575" @default.
• W4296622375 startingPage "100575" @default.
• W4296622375 abstract "•The addition of ARTA or docetaxel to ADT improved survival in mHSPC.•Recently, the combination of ARTA plus docetaxel and ADT (triplet) versus docetaxel plus ADT has been investigated.•The triplet prolonged OS and PFS compared with docetaxel plus ADT and represents a potential practice-changing treatment.•Clinical characteristics and drug safety profile may help clinicians to select the appropriate treatment for mHSPC. BackgroundAndrogen-deprivation therapy (ADT) historically represented the milestone for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). Recently, combining androgen receptor-targeted agents (ARTA) or docetaxel with ADT significantly improved clinical outcomes in this setting. The efficacy of the combined use of an ARTA with docetaxel and ADT (triplet), however, was unknown, and often conflicting data derived from subgroup analysis of randomized phase III trials. In order to better define the benefits and risks of the triplet in mHSPC, we carried out a systematic review and meta-analysis of available clinical trials.MethodsA literature search with no data restriction using Medline/PubMed, the Cochrane Library, and American Society of Clinical Oncology/European Society for Medical Oncology (ASCO/ESMO) Meeting abstracts was carried out up to April 2022. The meta-analysis was conducted following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statements. Overall survival (OS) was the primary endpoint; progression-free survival (PFS) and safety were secondary endpoints. For OS and PFS, summary hazard ratios (HRs) were calculated; for safety, risk ratio (RR) was assessed. Random- or fixed-effects models were used, depending on studies heterogeneity.ResultsFive randomized clinical trials fulfilled the prespecified inclusion criteria. The triplet significantly improved OS (fixed-effect, HR = 0.74; P < 0.00001) and PFS (fixed-effect; HR = 0.50 for clinical PFS, HR = 0.49 for radiological PFS; P < 0.0001) compared with docetaxel plus ADT. We did not show heterogeneity between treatment efficacy and the disease burden, metachronous versus synchronous presentation, concomitant versus sequential strategy. Compared with docetaxel + ADT, the triplet did not increase the risk of adverse events (AEs) (RR = 1.00, P = 0.27 for any-grade AEs; RR = 1.13, P = 0.14 for severe AEs), except for severe hypertension (RR = 1.73, P = 0.001).ConclusionsEmerging evidence supports the combination of an ARTA plus docetaxel and ADT in mHSPC patients. Given the availability of several strategies in this setting, clinical characteristics and drug safety profile may help clinicians select the appropriate treatment for mHSPC patients who are more likely to benefit from treatment intensification. Androgen-deprivation therapy (ADT) historically represented the milestone for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). Recently, combining androgen receptor-targeted agents (ARTA) or docetaxel with ADT significantly improved clinical outcomes in this setting. The efficacy of the combined use of an ARTA with docetaxel and ADT (triplet), however, was unknown, and often conflicting data derived from subgroup analysis of randomized phase III trials. In order to better define the benefits and risks of the triplet in mHSPC, we carried out a systematic review and meta-analysis of available clinical trials. A literature search with no data restriction using Medline/PubMed, the Cochrane Library, and American Society of Clinical Oncology/European Society for Medical Oncology (ASCO/ESMO) Meeting abstracts was carried out up to April 2022. The meta-analysis was conducted following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statements. Overall survival (OS) was the primary endpoint; progression-free survival (PFS) and safety were secondary endpoints. For OS and PFS, summary hazard ratios (HRs) were calculated; for safety, risk ratio (RR) was assessed. Random- or fixed-effects models were used, depending on studies heterogeneity. Five randomized clinical trials fulfilled the prespecified inclusion criteria. The triplet significantly improved OS (fixed-effect, HR = 0.74; P < 0.00001) and PFS (fixed-effect; HR = 0.50 for clinical PFS, HR = 0.49 for radiological PFS; P < 0.0001) compared with docetaxel plus ADT. We did not show heterogeneity between treatment efficacy and the disease burden, metachronous versus synchronous presentation, concomitant versus sequential strategy. Compared with docetaxel + ADT, the triplet did not increase the risk of adverse events (AEs) (RR = 1.00, P = 0.27 for any-grade AEs; RR = 1.13, P = 0.14 for severe AEs), except for severe hypertension (RR = 1.73, P = 0.001). Emerging evidence supports the combination of an ARTA plus docetaxel and ADT in mHSPC patients. Given the availability of several strategies in this setting, clinical characteristics and drug safety profile may help clinicians select the appropriate treatment for mHSPC patients who are more likely to benefit from treatment intensification." @default.
• W4296622375 created "2022-09-23" @default.
• W4296622375 creator A5007575010 @default.
• W4296622375 creator A5036574244 @default.
• W4296622375 creator A5037756908 @default.
• W4296622375 creator A5038576978 @default.
• W4296622375 creator A5046559582 @default.
• W4296622375 creator A5053526286 @default.
• W4296622375 creator A5065922277 @default.
• W4296622375 creator A5071060598 @default.
• W4296622375 creator A5073509869 @default.
• W4296622375 date "2022-10-01" @default.
• W4296622375 modified "2023-10-07" @default.
• W4296622375 title "Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis" @default.
• W4296622375 cites W1480729244 @default.
• W4296622375 cites W1986215651 @default.
• W4296622375 cites W2038693293 @default.
• W4296622375 cites W2107328434 @default.
• W4296622375 cites W2123629153 @default.
• W4296622375 cites W2125435699 @default.
• W4296622375 cites W2150865892 @default.
• W4296622375 cites W2214621962 @default.
• W4296622375 cites W2315123323 @default.
• W4296622375 cites W2423925663 @default.
• W4296622375 cites W2620746860 @default.
• W4296622375 cites W2620798309 @default.
• W4296622375 cites W2787804990 @default.
• W4296622375 cites W2788160989 @default.
• W4296622375 cites W2788841415 @default.
• W4296622375 cites W2802053856 @default.
• W4296622375 cites W2894350218 @default.
• W4296622375 cites W2897236707 @default.
• W4296622375 cites W2919810454 @default.
• W4296622375 cites W2947014957 @default.
• W4296622375 cites W2947893479 @default.
• W4296622375 cites W2963794755 @default.
• W4296622375 cites W2966112499 @default.
• W4296622375 cites W2969575782 @default.
• W4296622375 cites W3158318954 @default.
• W4296622375 cites W3164510972 @default.
• W4296622375 cites W3202107108 @default.
• W4296622375 cites W4206841660 @default.
• W4296622375 cites W4213196409 @default.
• W4296622375 cites W4223443163 @default.
• W4296622375 doi "https://doi.org/10.1016/j.esmoop.2022.100575" @default.
• W4296622375 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36152486" @default.
• W4296622375 hasPublicationYear "2022" @default.
• W4296622375 type Work @default.
• W4296622375 citedByCount "6" @default.
• W4296622375 countsByYear W42966223752023 @default.
• W4296622375 crossrefType "journal-article" @default.
• W4296622375 hasAuthorship W4296622375A5007575010 @default.
• W4296622375 hasAuthorship W4296622375A5036574244 @default.
• W4296622375 hasAuthorship W4296622375A5037756908 @default.
• W4296622375 hasAuthorship W4296622375A5038576978 @default.
• W4296622375 hasAuthorship W4296622375A5046559582 @default.
• W4296622375 hasAuthorship W4296622375A5053526286 @default.
• W4296622375 hasAuthorship W4296622375A5065922277 @default.
• W4296622375 hasAuthorship W4296622375A5071060598 @default.
• W4296622375 hasAuthorship W4296622375A5073509869 @default.
• W4296622375 hasBestOaLocation W42966223751 @default.
• W4296622375 hasConcept C121608353 @default.
• W4296622375 hasConcept C126322002 @default.
• W4296622375 hasConcept C143998085 @default.
• W4296622375 hasConcept C168563851 @default.
• W4296622375 hasConcept C203092338 @default.
• W4296622375 hasConcept C207103383 @default.
• W4296622375 hasConcept C2777899217 @default.
• W4296622375 hasConcept C2780192828 @default.
• W4296622375 hasConcept C2781190966 @default.
• W4296622375 hasConcept C44249647 @default.
• W4296622375 hasConcept C535046627 @default.
• W4296622375 hasConcept C71924100 @default.
• W4296622375 hasConcept C95190672 @default.
• W4296622375 hasConceptScore W4296622375C121608353 @default.
• W4296622375 hasConceptScore W4296622375C126322002 @default.
• W4296622375 hasConceptScore W4296622375C143998085 @default.
• W4296622375 hasConceptScore W4296622375C168563851 @default.
• W4296622375 hasConceptScore W4296622375C203092338 @default.
• W4296622375 hasConceptScore W4296622375C207103383 @default.
• W4296622375 hasConceptScore W4296622375C2777899217 @default.
• W4296622375 hasConceptScore W4296622375C2780192828 @default.
• W4296622375 hasConceptScore W4296622375C2781190966 @default.
• W4296622375 hasConceptScore W4296622375C44249647 @default.
• W4296622375 hasConceptScore W4296622375C535046627 @default.
• W4296622375 hasConceptScore W4296622375C71924100 @default.
• W4296622375 hasConceptScore W4296622375C95190672 @default.
• W4296622375 hasIssue "5" @default.
• W4296622375 hasLocation W42966223751 @default.
• W4296622375 hasLocation W42966223752 @default.
• W4296622375 hasLocation W42966223753 @default.
• W4296622375 hasOpenAccess W4296622375 @default.
• W4296622375 hasPrimaryLocation W42966223751 @default.
• W4296622375 hasRelatedWork W1963763301 @default.
• W4296622375 hasRelatedWork W2035098213 @default.
• W4296622375 hasRelatedWork W2522846761 @default.
• W4296622375 hasRelatedWork W2728894889 @default.
• W4296622375 hasRelatedWork W2753537866 @default.

• next